ZACKS·2025-07-31 14:41Company Performance - Editas Medicine (EDIT) has gained approximately 98.4% year-to-date, significantly outperforming the average return of -5.4% for the Medical sector [4] - Editas Medicine currently holds a Zacks Rank of 2 (Buy), indicating a favorable outlook based on earnings estimate revisions [3][4] - The Zacks Consensus Estimate for Editas Medicine's full-year earnings has increased by 0.4% over the past quarter, reflecting improved analyst sentiment [4] Industry Context - Editas Medicine is part of the Medical - Biomedical and Genetics industry, which consists of 492 companies and ranks 147 in the Zacks Industry Rank [6] - The Medical - Biomedical and Genetics industry has seen an average gain of 1.5% this year, indicating that Editas Medicine is performing better than its industry peers [6] - Another stock in the Medical sector, Adherex Technologies Inc. (FENC), has also shown strong performance with a year-to-date return of 33.1% and a Zacks Rank of 2 (Buy) [5][6]